Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.

CONCLUSION: In heavily pretreated pancreatic adenocarcinoma patients, low-dose nab-paclitaxel-based chemotherapy was fairly tolerable with modest efficacy. PMID: 30852003 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30852003?dopt=Abstract

Source: J Formos Med Assoc - March 6, 2019 Category: General Medicine Authors: Yang SH, Guo JC, Hsu C, Kuo SH, Tien YW, Cheng AL, Yeh KH Tags: J Formos Med Assoc Source Type: research